Reviparin sodium (
clivarine) is a second generation
LMWH, developed with the aim of maximising the antithrombotic action while minimising the risk of haemorrhage.
Clivarine has been extensively studied in
acute coronary syndrome. Various clinical studies in
unstable angina and
acute coronary syndrome have proved that
clivarine in a dosage of 3436anti-Xa units twice daily is an effective
antithrombotic agent.
Clivarine has been shown to be as effective as
unfractionated heparin (UFH) in thromboprophylaxis and it has less incidence of local haematoma at injection site. At a daily dose of 1432 IU anti-Xa it was found to be as effective as UFH in preventing
deep vein thrombosis (DVT) in moderate risk surgery (general and abdominal) and reducing to a significant extent DVT in patients with
brace immobilisation of the legs. At a daily dose of 3436 IU anti-Xa
reviparin was as effective as UFH or
enoxaparin in preventing DVT in high risk orthopaedic surgery and as effective as UFH in prevention of DVT and/or
pulmonary embolism (PE) and/or mortality in high risk orthopaedic surgery. In patients with acute venous thrombo-
embolism (VTE),
reviparin was more effective than UFH in
thrombus reduction and at least as effective as UFH in the prevention of clinical recurrence of DVT and/or PE. The use of
reviparin is associated with a similar or lower incidence of
bleeding complications than UFH. The benefits of
reviparin sodium have been demonstrated in a number of clinical trials.